Fibrogen announces fda clearance of investigational new drug application for fg-3165, a galectin-9 targeting monoclonal antibody, for the treatment of patients with solid tumors

San francisco, june 03, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced that the u.s. food and drug administration (fda) has cleared the company's investigational new drug (ind) of fg-3165, a galectin-9 (gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high gal9 levels of expression.
FGEN Ratings Summary
FGEN Quant Ranking